Table 1

Clinical and molecular characteristics of the 439 patients

VariablesRangeMean/median or %No. of patients
Clinical variables    
    White blood cell count, × 109/L 0.3-278 52.0/29.8 (mean/median)  
    Bone marrow blast count, % 0-98 62.1/66 (mean/median)  
    Platelet count, × 109/L 3-998 78.9/52  
Patient characteristics    
    Age, y 15-60 42.11/43 (mean/median)  
    Sex (female)   219 
FAB classification    
    M0  3.6 16 
    M1  19.1 84 
    M2  23.2 102 
    M3  5 22 
    M4  18.5 81 
    M4Eo  6.2 27 
    M5  23.7 104 
    M6  1.1 5 
    RAEB  0.9 4 
    Not determined  4.8 21 
Cytogenetics    
    t(8;21)  8 35 
    inv (16)  8.2 36 
    t(15;17)  5.7 25 
    CN  43.5 192 
    CA  28.7 126 
    MK*  5.7 25 
Mutations    
    NPM1+  29.6 130 
    FLT3ITD+  26.9 118 
    FLT3TKD+  10.7 47 
    N-RAS+  987 43 
    K-RAS+  0.9 4 
    CEBPASM+  1.6 7 
    CEBPADM+  5.2 23 
    IDH1+  7.2 32 
    IDH2+  8.2 36 
    NPM1+ FLT3ITD+  15.3 67 
    NPM1+ FLT3ITD−  14.4 63 
    NPM1− FLT3ITD+  11.6 51 
    NPM1− FLT3ITD−  58.8 258 
VariablesRangeMean/median or %No. of patients
Clinical variables    
    White blood cell count, × 109/L 0.3-278 52.0/29.8 (mean/median)  
    Bone marrow blast count, % 0-98 62.1/66 (mean/median)  
    Platelet count, × 109/L 3-998 78.9/52  
Patient characteristics    
    Age, y 15-60 42.11/43 (mean/median)  
    Sex (female)   219 
FAB classification    
    M0  3.6 16 
    M1  19.1 84 
    M2  23.2 102 
    M3  5 22 
    M4  18.5 81 
    M4Eo  6.2 27 
    M5  23.7 104 
    M6  1.1 5 
    RAEB  0.9 4 
    Not determined  4.8 21 
Cytogenetics    
    t(8;21)  8 35 
    inv (16)  8.2 36 
    t(15;17)  5.7 25 
    CN  43.5 192 
    CA  28.7 126 
    MK*  5.7 25 
Mutations    
    NPM1+  29.6 130 
    FLT3ITD+  26.9 118 
    FLT3TKD+  10.7 47 
    N-RAS+  987 43 
    K-RAS+  0.9 4 
    CEBPASM+  1.6 7 
    CEBPADM+  5.2 23 
    IDH1+  7.2 32 
    IDH2+  8.2 36 
    NPM1+ FLT3ITD+  15.3 67 
    NPM1+ FLT3ITD−  14.4 63 
    NPM1− FLT3ITD+  11.6 51 
    NPM1− FLT3ITD−  58.8 258 

Mutation present (or absent) groups denoted with (+) or (−).

RAEB indicates refractory anemia with excess blasts; FAB, French-American-British; CN, normal cytogenetics or -X or -Y as the sole abnormality; CA, cytogenetically abnormal; MK, monosomal karyotype; and M4Eo, M4 category with inv(16).

*

MK category contains 12 AML patients classified as complex karyotype and 13 other cases with complex karyotypes are in the CA category.

View Large